Astrana Health (ASTH) drew investor attention after releasing second quarter 2026 results and fresh guidance, alongside plans for further tuck in acquisitions in its Care Delivery expansion markets.

Astrana Health's recent earnings beat and updated 2026 guidance appear to be feeding into a strong year to date share price return of 57.61%. However, the 30 day share price return is down 11.55% and the 5 year total shareholder return is down 44.72%, which suggests long term holders have had a more difficult experience even as shorter term momentum has improved.

If Astrana Health's latest move has you thinking about where else growth and consolidation stories might emerge in healthcare, this is a good moment to broaden your search with the 40 healthcare AI stocks

Astrana Health now combines a strong year to date share price move with improving earnings and fresh acquisition plans. Do those positives still give buyers a reasonable margin of safety at today’s valuation?

Most Popular Narrative: 20.7% Undervalued

The most followed narrative currently places Astrana Health's fair value at about $50.13, compared with a last close of $39.75, which frames the stock as materially discounted on those assumptions.

Continued transition to full risk, value-based care contracts (now 78% of revenue, up from 60% YoY) is driving recurring, higher-quality revenue streams and improved patient retention. This positions Astrana to benefit from rising demand for coordinated, efficient healthcare as the U.S. population ages, which may support both revenue growth and sustainable margin expansion over time.

Want to see what kind of revenue mix, margin lift, and future earnings power need to line up to support that fair value gap? The full narrative lays out a detailed set of growth and profitability assumptions, including how value based contracts, integration progress and capital allocation choices all have to come together for Astrana Health.

Result: Fair Value of $50.13 (UNDERVALUED)

However, Astrana Health's reliance on government reimbursement and the execution risk around Prospect integration could still undermine that 20.7% undervalued narrative if things go off track.

Another View: Astrana Health On Earnings Multiples

The story looks different when you switch from fair value models to simple earnings multiples. Astrana Health trades on a P/E of 50.2x, compared with 25.3x for the wider US Healthcare sector and 27.2x for peers, while its fair ratio is 36.9x. That gap points to meaningful valuation risk if sentiment cools.

For a closer look at how this earnings multiple compares with other checks and what it could mean for future upside or downside, take a look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation and sentiment around Astrana Health, this is the time to look through the full picture of risks and rewards yourself. To weigh those trade offs quickly and form your own view, start with the 4 key rewards and 1 important warning sign.

Looking For More Investment Ideas Beyond Astrana Health?

If Astrana Health has sparked your interest, do not stop there. Use Simply Wall Street’s screener tools to uncover more opportunities that could fit your approach.

• Target potential value opportunities by scanning 53 high quality undervalued stocks that pair strong fundamentals with attractive pricing.
• Prioritise resilience by reviewing 80 resilient stocks with low risk scores that score well on financial strength and stability checks.
• Hunt for overlooked opportunities with the screener containing 19 high quality undiscovered gems before the rest of the market pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.